Cue Biopharma (NASDAQ:CUE) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Cue Biopharma (NASDAQ:CUE) from a buy rating to a strong-buy rating in a research note released on Monday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cue Biopharma in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cue Biopharma currently has a consensus rating of “Sell”.

Cue Biopharma Trading Down 10.5%

Shares of NASDAQ:CUE opened at $31.32 on Monday. The company has a fifty day simple moving average of $245.26 and a 200 day simple moving average of $350.73. The firm has a market cap of $101.48 million, a PE ratio of -3.26 and a beta of 2.37. Cue Biopharma has a 12-month low of $4.97 and a 12-month high of $41.42.

Hedge Funds Weigh In On Cue Biopharma

Hedge funds have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. boosted its holdings in Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after purchasing an additional 73,000 shares during the period. Squarepoint Ops LLC acquired a new position in Cue Biopharma in the third quarter worth $62,000. Stifel Financial Corp boosted its holdings in Cue Biopharma by 25.4% in the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares during the period. Texas Capital Bank Wealth Management Services Inc boosted its holdings in Cue Biopharma by 1,231.2% in the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares during the period. Finally, Boothbay Fund Management LLC boosted its holdings in shares of Cue Biopharma by 15.3% during the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after acquiring an additional 93,333 shares during the period. Institutional investors and hedge funds own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.